PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
10.26%
Revenue growth exceeding 1.5x VET's 0.39%. David Dodd would verify if faster growth reflects superior business model.
13.93%
Cost growth above 1.5x VET's 3.82%. Michael Burry would check for structural cost disadvantages.
7.26%
Positive growth while VET shows decline. John Neff would investigate competitive advantages.
-2.72%
Both companies show margin pressure. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
40.21%
Other expenses change of 40.21% while VET maintains costs. Bruce Berkowitz would investigate efficiency.
34.06%
Operating expenses growth while VET reduces costs. John Neff would investigate differences.
22.21%
Total costs growth while VET reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
6.89%
D&A growth while VET reduces D&A. John Neff would investigate differences.
-8.23%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-28.89%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-31.56%
Operating income decline while VET shows 2.38% growth. Joel Greenblatt would examine position.
-37.93%
Operating margin decline while VET shows 1.98% growth. Joel Greenblatt would examine position.
239.88%
Other expenses growth while VET reduces costs. John Neff would investigate differences.
-11.18%
Both companies show declining income. Martin Whitman would check industry conditions.
-19.44%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-68.20%
Tax expense reduction while VET shows 10.24% growth. Joel Greenblatt would examine advantage.
22.31%
Net income growth while VET declines. John Neff would investigate advantages.
10.93%
Net margin growth while VET declines. John Neff would investigate advantages.
-8.55%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-8.55%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Diluted share reduction while VET shows 10.13% change. Joel Greenblatt would examine strategy.